Capricor stock falls as FDA raises fresh questions

Capricor Therapeutics (NASDAQ: CAPR) came under pressure after the FDA released briefing documents ahead of the company’s July 29 advisory committee meeting for deramiocel, its investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy. The documents appeared to raise doubts about whether Capricor’s clinical package is strong enough to support approval, and that pushed the stock lower, down roughly 60%.

• Capricor shares dropped after the FDA posted briefing documents before the July 29 advisory committee meeting.
• The meeting will review Capricor’s application for deramiocel in Duchenne muscular dystrophy cardiomyopathy.
• The FDA emphasized that substantial evidence of effectiveness is generally expected for approval.
• The agency’s comments suggest it may want a stronger case before moving forward.
• The PDUFA target date remains August 22, 2026.

What the FDA briefing documents suggested

The FDA’s comments centered on the standard regulators use when deciding whether a drug should be approved. The agency said substantial evidence of effectiveness is generally required, which is a reminder that high-level clinical promise is not always enough on its own. That framing matters because Capricor’s filing appears to rely heavily on the HOPE-3 Phase 3 study.

Why traders reacted so sharply

Capricor has already had a difficult regulatory path, including an earlier rejection from the FDA that cited insufficient evidence of effectiveness. The latest briefing documents brought those concerns back into focus just days before the advisory committee meeting. For traders, that created a very clear binary setup, where the stock could move sharply based on how regulators interpret the data.

What happens next in the review process

The advisory committee meeting is set for July 29, 2026, and it will be a major checkpoint for deramiocel. The FDA’s PDUFA target date is still August 22, 2026, so investors now have two key dates to watch closely. If the agency remains skeptical after the panel, the approval path could become even more difficult.

Investor takeaway

For investors, CAPR now looks like a high-risk, event-driven biotech name with major volatility still ahead. The upside depends on whether Capricor can convince regulators that its Phase 3 package is enough, while the downside is another possible regulatory setback. In this kind of setup, the FDA’s interpretation of the data may matter as much as the clinical results themselves.